Drug intelligence / Profile preview

bimatoprost (Allergan)

Development stage
Approved
Lead developer
AbbVie
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Bimatoprost SR (marketed as Durysta) is a sterile, biodegradable, intracameral sustained-release implant containing the prostaglandin analog bimatoprost. Developed by Allergan (now part of AbbVie), it is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The implant is designed to be administered into the anterior chamber of the eye, where it slowly releases bimatoprost over several months, providing a continuous therapeutic effect and potentially overcoming issues related to patient non-adherence with daily topical eye drops. Bimatoprost works by increasing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral pathways, thereby lowering IOP.

Brand names
Durysta
Other names
Bimatoprost sustained-release implantBimatoprost intracameral implant
02

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on bimatoprost (Allergan).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bimatoprost (Allergan).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call